View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 17, 2017updated 13 Jul 2022 10:10am

Capecitabine improves post-surgery survival period in bile duct cancer patients

A Cancer Research UK-funded trial (BILCAP) showed that the chemotherapy drug capecitabine increased the survival period of bile duct cancer patients by up to one and a half years after undergoing surgery for the disease.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A Cancer Research UK-funded trial (BILCAP) showed that the chemotherapy drug capecitabine increased the survival period of bile duct cancer patients by up to one and a half years after undergoing surgery for the disease.

Available under the brand name Xeloda, capecitabine is an anti-metabolite drug developed to inhibit the DNA repair and production of tumour cells.

It is indicated for the treatment of various cancers such as oesophagal cancer, bowel cancer, pancreatic cancer, breast cancer and stomach cancer.

BILCAP is a randomised trial designed to evaluate the ability of the drug to prevent cancer recurrence after surgical removal of bile duct cancer or gallbladder cancer.

The trial compared effects of surgery and capecitabine with surgery alone in approximately 450 patients.

Lead researcher Professor John Primrose said: “While rare, bile duct cancer is difficult to treat and until recently there has been very little progress in treating the disease.

"Our results clearly show that patients who have surgery should be given capecitabine, as a result of which more will survive and with few side effects."

“Our results clearly show that patients who have surgery should be given capecitabine, as a result of which more will survive and with few side effects.”

The results indicated that the three-year survival period increased by 23% and the average survival increased from 36 to 53 months in patients who received capecitabine after their surgery of bile duct cancer.

Cancer Research UK chief clinician Professor Peter Johnson said: “Rare cancers like this have previously been a difficult problem, but by organising large trials, in many cases with international collaboration, we can find better ways to look after people with these illnesses. 

“Speeding up progress is going to depend on better laboratory science to understand the processes that drive cancer cells and smart trials to use this knowledge to the best effect.”


Image: Micrograph of bile duct cancer. Photo: courtesy of Nephron.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena